<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00909168</url>
  </required_header>
  <id_info>
    <org_study_id>MYFLAI07</org_study_id>
    <nct_id>NCT00909168</nct_id>
  </id_info>
  <brief_title>Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML)</brief_title>
  <acronym>MYFLAI07</acronym>
  <official_title>Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Udine, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Udine, Italy</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, open, non-randomized, non-controlled, phase II, clinical trial for&#xD;
      treatment of newly diagnosed AML patients, younger than 66 years.&#xD;
&#xD;
      Trial is based on:&#xD;
&#xD;
        -  INDUCTION: FLAI + Gemtuzumab-Ozogamicin (FLAI-GO).&#xD;
&#xD;
        -  CONSOLIDATION: Intermediate dose AraC + IDA (IDAC+IDA) +/- one course of high dose AraC&#xD;
           (HDAC)&#xD;
&#xD;
        -  INTENSIFICATION: Allo-BMT, ASCT&#xD;
&#xD;
        -  MAINTENANCE: AraC&#xD;
&#xD;
           a) Primary endpoints:&#xD;
&#xD;
        -  Feasibility, Efficacy (CR+PR rate) and Toxicity of FLAI + Gemtuzumab-Ozogamicin.&#xD;
&#xD;
        -  RFS, DFS and OS.&#xD;
&#xD;
           b) Secondary endpoints:&#xD;
&#xD;
        -  Evaluation of Minimal Residual Disease by WT1 (and other biologic markers) expression&#xD;
           and monitoring.&#xD;
&#xD;
        -  Evaluation of prognostic clinical relevance of biological features at onset.&#xD;
&#xD;
        -  Feasibility and outcome of consolidation with BMT.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility, Efficacy (CR+PR rate) and Toxicity of FLAI + Gemtuzumab-Ozogamicin.</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>RFS, DFS and OS.</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Minimal Residual Disease by WT1 (and other biologic markers) expression and monitoring.</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of prognostic clinical relevance of biological features at onset.</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility and outcome of consolidation with BMT.</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Efficacy of FLAIMy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FLAIMy - Fluda, Ida, Ara-C, Mylotarg</intervention_name>
    <description>FLUDARABINE: 25 mg/m2/day, 250 FS in 30', start h 9 - 1, 2, 3, 4, 5&#xD;
ARABINOSYL-CYTOSINE (Cytarabine): 2 g/m2/day, 500 FS in 3 h, start h 13 - 1, 2, 3, 4, 5&#xD;
IDARUBICIN: 10 mg/m2/day, 100 FS in 1 h, start h 16 - 1, 3, 5&#xD;
GEMTUZUMAB OZOGAMICIN (Mylotarg): 5 mg, single dose 500 FS in 4 h - 6</description>
    <arm_group_label>Efficacy of FLAIMy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-65 years.&#xD;
&#xD;
          -  WHO PS grade 0-2 (Appendix B) or Karnofsky &gt; 70.&#xD;
&#xD;
          -  AML according to the new WHO criteria, i.e., % of BM blasts ≥ 20%. NB. this % should&#xD;
             be assessed on a BM aspiration or on a BM biopsy&#xD;
&#xD;
          -  All FAB subtypes except M3.&#xD;
&#xD;
          -  CD33 positivity (&gt; 20%). It is mandatory to perform an immunotyping of the BM blasts&#xD;
             in particular the determination of CD33 positivity, which will be used as a inclusion&#xD;
             factor.&#xD;
&#xD;
          -  Previously untreated (except ≤ 14 days of Hydroxyurea) primary or secondary AML&#xD;
             (including AML after MDS).&#xD;
&#xD;
          -  Adequate renal and liver function, i.e., creatinine &lt; 2 mg/dl and bilirubin, ALT/AST ≤&#xD;
             3 times the upper limit of normal.&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Blast crisis of chronic myeloid leukemia.&#xD;
&#xD;
          -  AML supervening after other myeloproliferative diseases.&#xD;
&#xD;
          -  AML de novo or secondary previously pretreated.&#xD;
&#xD;
          -  Concomitant malignant disease.&#xD;
&#xD;
          -  Active central nervous system (CNS) leukemia.&#xD;
&#xD;
          -  Active uncontrolled infection [NB severe systemic infection should be excluded].&#xD;
&#xD;
          -  Concomitant severe cardiovascular disease, i.e., arrhythmias requiring chronic&#xD;
             treatment, congestive heart failure or symptomatic ischemic heart disease.&#xD;
&#xD;
          -  Cardiac ejection fraction of 50% or less.&#xD;
&#xD;
          -  Severe pulmonary dysfunction (CTC grade 3-4).&#xD;
&#xD;
          -  Severe concomitant neurological or psychiatric disease.&#xD;
&#xD;
          -  History of alcohol abuse.&#xD;
&#xD;
          -  HIV positivity.&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Man and woman not agreeing to the adequate contraceptive precautions during study&#xD;
             period and for at last 24 months after stop of therapy.&#xD;
&#xD;
          -  Any psychological, familiar, sociological or geographical condition potentially&#xD;
             hampering compliance with the study protocol and follow-up schedule.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ANNA CANDONI, MD</last_name>
    <role>Study Director</role>
    <affiliation>UUNIVERSITY HOSPITAL, UDINE, ITALY</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital, Udine</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>May 26, 2009</study_first_submitted>
  <study_first_submitted_qc>May 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2009</study_first_posted>
  <last_update_submitted>May 5, 2014</last_update_submitted>
  <last_update_submitted_qc>May 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Udine, Italy</investigator_affiliation>
    <investigator_full_name>CANDONI ANNA</investigator_full_name>
    <investigator_title>Division of Hematology, SM MISERICORDIA HOSPITAL</investigator_title>
  </responsible_party>
  <keyword>Induction chemotherapy</keyword>
  <keyword>Fludarabine</keyword>
  <keyword>Gemtuzumab Ozogamicin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemtuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

